AstraZeneca (LON:AZN) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

AstraZeneca PLC (LON:AZN - Get Free Report)'s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of £108.83 ($148.17) and traded as high as £109.10 ($148.54). AstraZeneca shares last traded at £109.06 ($148.48), with a volume of 1,476,352 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have commented on AZN shares. Berenberg Bank reaffirmed a "buy" rating and issued a GBX 140 ($1.91) price objective on shares of AstraZeneca in a report on Friday, May 16th. JPMorgan Chase & Co. reaffirmed an "overweight" rating on shares of AstraZeneca in a report on Wednesday, February 19th. Finally, Shore Capital reiterated a "buy" rating on shares of AstraZeneca in a research note on Tuesday, April 29th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of GBX 6,303.50 ($85.82).

AstraZeneca Stock Performance

The firm's 50 day simple moving average is £103.78 and its 200-day simple moving average is £108.83. The company has a market capitalization of £211.29 billion, a price-to-earnings ratio of 30.10, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.